Distributor inventory | Tablet
Dapagliflozin 10 mg + Metformin hydrochloride 1000 mg (likely prolonged/extended release)
Type 2 diabetes mellitus (to improve glycaemic control as an adjunct to diet and exercise); may be used when dual therapy is required
Dapagliflozin (an SGLT2 inhibitor) lowers blood glucose by increasing urinary glucose excretion via the kidneys. Metformin reduces hepatic glucose production and improves insulin sensitivity, helping the body use insulin more effectively.
Oral tablet. Take exactly as prescribed. Usually taken once daily with food (preferably with/after the main meal) to reduce stomach upset; swallow whole if extended-release—do not crush or chew. Maintain adequate hydration.
Common side effects of DAPA CAD M 1000 TAB may include:
Prescription-only antidiabetic. Risk of lactic acidosis with metformin (higher in kidney impairment, dehydration, heavy alcohol use, severe infection, shock, liver disease); kidney function should be assessed before and during therapy. Dapagliflozin may cause dehydration/low blood pressure, genital/urinary infections, and rarely ketoacidosis (can occur even with near-normal sugars)—seek urgent care for nausea, vomiting, abdominal pain, rapid breathing. Stop temporarily during acute illness, prolonged fasting, major surgery, or before iodinated contrast procedures as advised. Monitor for hypoglycaemia when used with insulin/sulfonylureas. Not for type 1 diabetes.
